Anebulo Pharmaceuticals (NASDAQ:ANEB) is a company focused on developing innovative solutions to address acute cannabinoid intoxication and improve public health. Its operations revolve around researching and creating effective treatments for symptoms associated with acute cannabinoid overdose, such as panic, anxiety, and psychosis. Through its various projects, Anebulo Pharmaceuticals aims to lead the way in providing reliable, scientifically backed options for individuals who have inadvertently consumed excessive amounts of cannabinoids. The company's primary objective is to advance its pipeline of treatments to meet the urgent needs of patients and healthcare providers in this emerging area of medical concern, ensuring safety and efficacy are at the forefront of its mission.